Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences

HK A+H IPO 2026: Performance Drivers, Premium Dynamics, and 2W Return Attribution

HK Biotech IPO 2025: A Statistical Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Contemporary Amperex Technology / Equity Capital Markets

Contemporary Amperex Technology (3750 HK)

<ul>
<li>In this note, we take a statistical view of the A+H listing in 2025.</li>
<li>We examine time-series trends in IPO performance, subscription dynamics, market sentiment, and sponsor performance.</li>
<li>We also look at A-H premium dynamics post-listing and sector-level deal performance.</li>
</ul>


In this note, we take a statistical view of the A+H listing in 2025.
We examine time-series trends in IPO performance, subscription dynamics, market sentiment, and sponsor performance.
We also look at A-H premium dynamics post-listing and sector-level deal performance.


Jiangsu Hengrui Pharmaceuticals (1276 HK)

HK A+H IPO 2025: Essential Statistics Ahead of the 2026 Wave